Today: 13 June 2026
NAB share price slips as rate bets shift; key dates ahead for National Australia Bank stock
10 January 2026
1 min read

NAB share price slips as rate bets shift; key dates ahead for National Australia Bank stock

SYDNEY, Jan 10, 2026, 17:16 AEDT — Market closed

National Australia Bank Ltd (ASX:NAB) shares ended 0.2% lower at A$41.02 on Friday, with ANZ down 0.6%, Westpac off 0.3% and Commonwealth Bank down 0.1% as financials weighed on the session. The benchmark S&P/ASX 200 closed down 3 points at 8,717.80.

That matters because the big banks trade like rate proxies. When traders pull forward or push out a move by the Reserve Bank of Australia, it can hit expectations for net interest margin — the gap between what a bank earns on loans and pays on deposits and funding.

RBA officials have tried to keep the market from getting too relaxed. “Inflation above 3% — let’s be clear, it’s too high,” Deputy Governor Andrew Hauser said, after data showed November’s annual inflation cooled but stayed above the central bank’s 2%-3% target band. Reuters

The inflation read itself has been messy. Data showed headline CPI slowed to 3.4% year-on-year in November, while the trimmed mean — a core measure that strips out big one-off moves — eased to 3.2%, and Reuters reported investors still saw a 33% risk of a February hike. Harry Murphy Cruise, head of economic research at Oxford Economics Australia, called 3.2% “the magic number” for the trimmed mean in the late-January quarterly read. Reuters

The next test lands on Jan. 28, when the Australian Bureau of Statistics is due to release December CPI, alongside updates to the quarterly CPI tables. That print will shape how hard traders lean into the February rates call.

For NAB, the next marker is its first-quarter trading update on Feb. 18, with half-year results due May 4, according to the bank’s financial calendar. Investors typically use those updates to gauge loan growth, deposit pricing and costs, and whether bad-debt pressures are creeping in.

Technically, NAB has slipped 2.77% so far in 2026 and sits just under its 50-day moving average of A$41.74. The stock is about 9% below its 52-week high of A$45.25 set on Nov. 6, 2025, and above the 52-week low of A$31.13.

But the new monthly inflation series can whip around, and banks can get hit from both sides: higher rates can lift margins but also strain borrowers. Any upside surprise in inflation, or a renewed fight for deposits, would make it harder for NAB to hold recent levels.

With the ASX shut over the weekend, attention turns to Monday’s reopen and whether bank sellers return early. The next hard dates are the RBA’s Feb. 2–3 meeting and NAB’s Feb. 18 trading update.

Stock Market Today

  • Soybean Prices Hold Steady Amid Mixed USDA Data and Export Sales
    June 13, 2026, 3:58 PM EDT. Soybean prices edged lower by 1 to 2 cents on Friday midday, with the national average cash bean price at $10.60 1/2. Futures for soymeal showed mixed movement, while soy oil dropped between 20 to 36 points. The USDA's latest export sales report indicates the 2025/26 soybean business at 40.15 million metric tons (MMT), trailing the revised USDA projection and average sales pace at 97.7%. Shipments stand at 36 MMT or 87.6% of USDA estimates. WASDE data revealed steady old and new crop U.S. stocks. Brazilian and Argentine production forecasts remain stable at 180 MMT and 50 MMT, respectively. Market watchers await Monday's NOPA data for insight on May crush and soybean oil stocks.

Latest articles

KLA Jumps After 10-for-1 Stock Split; AI Chip Boom Lifts Hopes on Tools

KLA Jumps After 10-for-1 Stock Split; AI Chip Boom Lifts Hopes on Tools

13 June 2026
KLA soared 5.55% to $254.54 on its first split-adjusted day after a 10-for-1 stock split and analyst price target hikes tied to AI-driven chip equipment demand, but with the stock now above several split-adjusted targets, investors face heightened risk ahead of the fiscal Q4 report, which will be the next key catalyst for revenue, earnings, and AI-linked demand guidance.
Pfizer trades around $26 with dividend in focus, drug-price worries linger

Pfizer trades around $26 with dividend in focus, drug-price worries linger

13 June 2026
Pfizer closed at $26.21, up 0.15%, outperforming the Health Care Select Sector SPDR ETF despite new German drug-pricing pressures and a European legal setback; investors are focused on the 6.56% dividend yield, reaffirmed 2026 guidance, and pipeline progress in obesity and oncology as Q2 earnings on August 4 approach.
Adobe stock slides on BMO downgrade: “no clear catalyst” and competition in focus
Previous Story

Adobe stock slides on BMO downgrade: “no clear catalyst” and competition in focus

Lloyds share price clings to £1 as investors eye inflation data and Jan 29 results
Next Story

Lloyds share price clings to £1 as investors eye inflation data and Jan 29 results

Go toTop